Tumor Immunology

Every cell in a multicellular organism has the potential to die by apoptosis, but tumour cells often have faulty apoptotic pathways. These defects not only increase tumour mass, but also render the tumour resistant to therapy. So, what are the molecular mechanisms of tumour resistance to apoptosis and how can we use this knowledge to resensitize tumour cells to cancer therapy?

[1]  J. M. Lee,et al.  p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Strasser,et al.  The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. , 1999, Molecular cell.

[3]  A. Fersht,et al.  Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.

[4]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[5]  D. Brash,et al.  Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. , 2001, The Journal of clinical investigation.

[6]  G. Evan,et al.  c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.

[7]  J. Bertin,et al.  Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Mak,et al.  Modulation of cellular apoptotic potential: contributions to oncogenesis , 1999, Oncogene.

[9]  G. Salvesen,et al.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.

[10]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[11]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[12]  S. Rosenberg,et al.  implications for cancer therapy , 1996 .

[13]  M. Peter,et al.  Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells , 1998, Cell Death and Differentiation.

[14]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[15]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[16]  M. Shin,et al.  Alterations of the DR 5 / TRAIL Receptor 2 Gene in Non-Small Cell Lung Cancers 1 Sug , 1999 .

[17]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Weller,et al.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. , 1995, The Journal of clinical investigation.

[19]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Jian Ni,et al.  A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis* , 1999, The Journal of Biological Chemistry.

[21]  T. Landowski,et al.  Mutations in the Fas antigen in patients with multiple myeloma. , 1997, Blood.

[22]  G. Kroemer,et al.  The mitochondrion in apoptosis: how Pandora's box opens , 2001, Nature Reviews Molecular Cell Biology.

[23]  D. Altieri,et al.  Inhibition of melanoma tumor growth in vivo by survivin targeting. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Dörken,et al.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. , 1996, The Journal of clinical investigation.

[25]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[26]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[27]  R. Testi,et al.  Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. , 1996, Journal of immunology.

[28]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[29]  J. Tschopp,et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors , 1997, Nature.

[30]  P. Galle,et al.  Reactive Oxygen Intermediates Are Involved in the Induction of CD95 Ligand mRNA Expression by Cytostatic Drugs in Hepatoma Cells* , 1997, The Journal of Biological Chemistry.

[31]  J. Jen,et al.  Rare loss-of-function mutation of a death receptor gene in head and neck cancer. , 1998, Cancer research.

[32]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[33]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[34]  P. Galle,et al.  The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. , 1999, European cytokine network.

[35]  S. Frisch,et al.  Disruption of epithelial cell-matrix interactions induces apoptosis , 1994, The Journal of cell biology.

[36]  C. Thompson,et al.  Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. , 1995, Cancer research.

[37]  L. Owen-Schaub,et al.  Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. , 1996, Cancer research.

[38]  P. Nowell,et al.  Oncogenic potential of bcl-2 demonstrated by gene transfer , 1988, Nature.

[39]  P. Krammer.  CD95(APO-1/Fas)-mediated apoptosis: live and let die. , 1999, Advances in immunology.

[40]  C. Thompson,et al.  The central effectors of cell death in the immune system. , 1999, Annual review of immunology.

[41]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[42]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[43]  H. Findley,et al.  Expression and Regulation of Bcl-2 , Bcl-xl , and Bax Correlate With p 53 Status and Sensitivity to Apoptosis in Childhood Acute Lymphoblastic Leukemia , 1997 .

[44]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[45]  H. S. Kim,et al.  Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. , 1999, Cancer research.

[46]  T. Ley,et al.  How do cytotoxic lymphocytes kill their targets? , 1998, Current opinion in immunology.

[47]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[48]  Asim Khwaja,et al.  Matrix adhesion and Ras transformation both activate a phosphoinositide 3‐OH kinase and protein kinase B/Akt cellular survival pathway , 1997, The EMBO journal.

[49]  P. Krammer,et al.  Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[50]  Phillip D. Zamore,et al.  RNA interference: listening to the sound of silence , 2001, Nature Structural Biology.

[51]  John Savill,et al.  Corpse clearance defines the meaning of cell death , 2000, Nature.

[52]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[53]  R. Johnstone,et al.  P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. , 1999, Blood.

[54]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[56]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[57]  M. Peter,et al.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. , 1997, Cancer research.

[58]  J. Xiang,et al.  BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Russo,et al.  Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue , 1997, Nature Medicine.

[60]  Xin Lu,et al.  ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.

[61]  P. Golstein,et al.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.

[62]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[64]  Aris Persidis,et al.  Cancer multidrug resistance , 1999, Nature Biotechnology.

[65]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[66]  S. Korsmeyer,et al.  Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. , 1998, Blood.

[67]  S. Ugurel,et al.  Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  A. Passaniti,et al.  Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. , 1995, Cancer research.

[69]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[70]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[71]  H. S. Kim,et al.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. , 2001, Cancer research.

[72]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[73]  M. Robinson,et al.  Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. , 1999, Genes & development.

[74]  P. Daniel,et al.  The kiss of death: promises and failures of death receptors and ligands in cancer therapy , 2001, Leukemia.

[75]  G. Chinnadurai,et al.  Epstein-Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection. , 1994, Virology.

[76]  G. Evan,et al.  Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.

[77]  I. H. Engels,et al.  Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. , 1999, Blood.

[78]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[79]  M. Peter,et al.  Cleavage of FLICE (caspase‐8) by granzyme B during cytotoxic T lymphocyte‐induced apoptosis , 1997, European journal of immunology.

[80]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[81]  M. Seldin,et al.  Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. , 1999, Blood.

[82]  S. Lowe,et al.  INK 4 a / ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53 , 1999 .

[83]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[84]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[85]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[86]  S. Lowe,et al.  Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.

[87]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[88]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[89]  D. Altieri,et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.

[90]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[91]  D. Bredesen,et al.  An alternative, nonapoptotic form of programmed cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[92]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[93]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[94]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[95]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[96]  F. Behm,et al.  Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. , 1996, Blood.

[97]  P. Krammer,et al.  A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs , 2000, Molecular and Cellular Biology.

[98]  A. Strasser,et al.  BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death , 2000, Cell.

[99]  G. Hannon.  RNA interference : RNA , 2002 .

[100]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[101]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[102]  W. Fiers,et al.  Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. , 1986, European journal of cancer & clinical oncology.

[103]  Shi-Yong Sun,et al.  Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated gene , 2001, Journal of cellular physiology.

[104]  K. Franssila,et al.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. , 1995, Cancer research.

[105]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[106]  D. Scott,et al.  Distinct Molecular Mechanisms of Fas Resistance in Murine B Lymphoma Cells1 , 2000, The Journal of Immunology.

[107]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[108]  M. Weller,et al.  Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. , 2001, Cancer research.

[109]  Timothy J. Ley,et al.  Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells , 1994, Cell.

[110]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[111]  K. Tamai,et al.  Identification of XAF1 as an antagonist of XIAP anti-Caspase activity , 2001, Nature Cell Biology.

[112]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[113]  J. Tschopp,et al.  Oncogenic Ras inhibits Fas ligand‐mediated apoptosis by downregulating the expression of Fas , 1999, The EMBO journal.

[114]  M. Tomonaga,et al.  Fas Gene Mutation in the Progression of Adult T Cell Leukemia , 1999, The Journal of experimental medicine.

[115]  Yusuke Nakamura,et al.  p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.

[116]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[117]  D. Green,et al.  Granzyme B–Mediated Cytochrome C Release Is Regulated by the Bcl-2 Family Members Bid and Bax , 2000, The Journal of experimental medicine.

[118]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[119]  C. Borner,et al.  Apoptosis without caspases: an inefficient molecular guillotine? , 1999, Cell Death and Differentiation.

[120]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[121]  T. Rebbeck,et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[122]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[123]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[124]  P. Galle,et al.  CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. , 1998, Advances in cancer research.

[125]  S. Frisch,et al.  Anoikis mechanisms. , 2001, Current opinion in cell biology.

[126]  J P Luzio,et al.  Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. , 1998, Science.

[127]  R. Hay,et al.  Defective IκBα in Hodgkin cell lines with constitutively active NF-κB , 1998, Oncogene.

[128]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[129]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[130]  Andreas Villunger,et al.  Bmf: A Proapoptotic BH3-Only Protein Regulated by Interaction with the Myosin V Actin Motor Complex, Activated by Anoikis , 2001, Science.

[131]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[132]  P. Monini,et al.  Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. , 1999, Journal of the National Cancer Institute.

[133]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[134]  J. Moul,et al.  Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector , 1997, International journal of cancer.

[135]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[136]  P. Krammer,et al.  Regulation of death receptor-mediated apoptosis pathways. , 2000, The international journal of biochemistry & cell biology.

[137]  K. Vousden,et al.  Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.

[138]  P. Biberfeld,et al.  The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors , 1999, The Journal of experimental medicine.

[139]  Lynda Chin,et al.  E.: “A Summary of , 1968 .

[140]  R. Gentz,et al.  I-FLICE, a Novel Inhibitor of Tumor Necrosis Factor Receptor-1- and CD-95-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[141]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[142]  Hans Hengartner,et al.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice , 1994, Nature.

[143]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[144]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[145]  K. Koretz,et al.  Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.

[146]  R. Offringa,et al.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[147]  D. Nicholson,et al.  From bench to clinic with apoptosis-based therapeutic agents , 2000, Nature.

[148]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[149]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[150]  J C Reed,et al.  The Survivin saga goes in vivo. , 2001, The Journal of clinical investigation.

[151]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[152]  D. Goeddel,et al.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.

[153]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[154]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[155]  A. Marx,et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.

[156]  John Calvin Reed,et al.  bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. , 1992, Cancer research.

[157]  R. Johnstone,et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[158]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[159]  Jean-Claude Martinou,et al.  Breaking the mitochondrial barrier , 2001, Nature Reviews Molecular Cell Biology.

[160]  I. Weissman,et al.  Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor α Chimeric Protein (Pmlrarα) to Block Neutrophil Differentiation and Initiate Acute Leukemia , 2001, The Journal of experimental medicine.

[161]  H. Findley,et al.  Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. , 1997, Blood.

[162]  D. Benbrook,et al.  Nature Reviews Cancer , 2003 .

[163]  J. Schatzle,et al.  Inhibition of the Death Receptor Pathway by cFLIP Confers Partial Engraftment of MHC Class I-Deficient Stem Cells and Reduces Tumor Clearance in Perforin-Deficient Mice1 , 2001, The Journal of Immunology.

[164]  I. Herr,et al.  Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.

[165]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[166]  A. Strasser,et al.  Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy , 2000 .

[167]  J. Li,et al.  Cancer gene therapy using a survivin mutant adenovirus. , 2001, The Journal of clinical investigation.

[168]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[169]  S. Korsmeyer,et al.  Bax suppresses tumorigenesis and stimulates apoptosis in vivo , 1997, Nature.

[170]  S. Fulda,et al.  Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. , 2001, Blood.

[171]  J. Tschopp,et al.  FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. , 1998, Journal of immunology.

[172]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[173]  J. Wyatt,et al.  Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides , 1999, Nature Biotechnology.

[174]  P. Galle,et al.  Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma , 2001, Journal of Molecular Medicine.

[175]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[176]  John Calvin Reed,et al.  Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[177]  G. Evan,et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.

[178]  A. Levine,et al.  Essential role for p53-mediated transcription in E1A-induced apoptosis. , 1995, Genes & development.

[179]  H. Cavé,et al.  Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. , 1998, Blood.

[180]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[181]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[182]  P. Marynen,et al.  The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. , 1999, Blood.

[183]  L. Harrington,et al.  Telomeres, telomerase, and cancer: life on the edge of genomic stability , 2000, Current opinion in oncology.

[184]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[185]  J. H. Li,et al.  The regulation of CD95 ligand expression and function in CTL. , 1998, Journal of immunology.